<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01754233</url>
  </required_header>
  <id_info>
    <org_study_id>CYN12-PICO-PL</org_study_id>
    <nct_id>NCT01754233</nct_id>
  </id_info>
  <brief_title>Evaluation of the 755nm Alexandrite for the Treatment of Epidermal and Dermal Pigmented Lesions</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynosure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess treatment for facial dermal and epidermal pigmented&#xD;
      lesions using the 755nm Alexandrite laser.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Photographic Evaluation</measure>
    <time_frame>up to 4 months post last treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reporting of Adverse Events</measure>
    <time_frame>up to 4 months post last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction Questionnaire</measure>
    <time_frame>up to 4 months post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Dermal and Epidermal Pigmented Lesions</condition>
  <arm_group>
    <arm_group_label>755nm Alexandrite Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>755nm Alexandrite Laser</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>755nm Alexandrite Laser</intervention_name>
    <description>755nm Alexandrite Laser for epidermal and dermal pigmented lesions</description>
    <arm_group_label>755nm Alexandrite Laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Is a healthy male or female between 18 and 85 years old&#xD;
&#xD;
          2. Has unwanted dermal and/or epidermal pigmented lesions or desires skin toning and&#xD;
             wishes to undergo laser treatments.&#xD;
&#xD;
          3. Is willing to consent to participate in the study.&#xD;
&#xD;
          4. Is willing to comply with all requirements of the study including being photographed,&#xD;
             following post treatment care and attending all treatment and follow up visits.&#xD;
&#xD;
          5. Has Fitzpatrick skin types III to IV.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subject is female and pregnant, has been pregnant within the last 3 months, is&#xD;
             currently breast feeding or planning a pregnancy during the study period.&#xD;
&#xD;
          2. The subject is hypersensitive to light exposure OR takes photo sensitized medication.&#xD;
&#xD;
          3. The subject has active or localized systemic infections&#xD;
&#xD;
          4. The subject has any condition which, in the investigator's opinion, would make it&#xD;
             unsafe for the subject to participate in this research study.&#xD;
&#xD;
          5. The subject is currently enrolled in an investigational drug or device trial, or has&#xD;
             received an investigational drug or been treated with an investigational device within&#xD;
             3 months prior to entering this study.&#xD;
&#xD;
          6. The subject has used Accutane within 6 months prior to enrollment.&#xD;
&#xD;
          7. The subject has the need to be exposed to artificial tanning devices or excessive&#xD;
             sunlight during the trial.&#xD;
&#xD;
          8. The subject has had prior treatment with parenteral gold therapy (gold sodium&#xD;
             thiomalate).&#xD;
&#xD;
          9. The subjects had prior treatment with laser or other devices in the treatment area&#xD;
             within 3 months.&#xD;
&#xD;
         10. The subject has a history of keloids or hypertrophic scarring.&#xD;
&#xD;
         11. The subject has evidence of compromised wound healing.&#xD;
&#xD;
         12. The subject has a history of squamous cell carcinoma or melanoma&#xD;
&#xD;
         13. The subject has a history of immunosuppression/immune deficiency disorders (including&#xD;
             HIV infection or AIDS) or use of immunosuppressive medications.&#xD;
&#xD;
         14. Is allergic to topical lidocaine or topical steroids.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Krantz</last_name>
    <role>Study Director</role>
    <affiliation>Cynosure, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skin Care Physicians</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 18, 2012</study_first_submitted>
  <study_first_submitted_qc>December 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2012</study_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

